Clinical trials: Primary Hypercholesterolaemia
Primary Hypercholesterolemia, Combined Hyperlipidemia
Study to Evaluate the Bioequivalence of "Crecheck Tablet 2.5 mg (Rosuvastatin Calcium)" and "Crestor Tablet 5 mg (Rosuvastatin Calcium)" in Healthy Adult Subjects
This clinical trial is an open, randomized, 2-group, 2-period, fasting, single-dose, crossover study to evaluate the bioequivalence of "Crecheck Tablet 2.5 mg (Rosuvastatin Calcium)" of Hanlim Pharm. Co., Ltd.
- Trial name
- NCT06475872
- Testing
- Crecheck Tablet 2.5 mg, Crestor Tablet 5 mg
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Hanlim Pharm. Co., Ltd.
Hypercholesterolemia
Red Yeast Rice for Primary Prevention of Hypercholesterolemia
This two-year observational study will be conducted at the outpatient clinic of the Department of Traditional Chinese Medicine of Taoyuan Chang Gung Hospital from February 26, 2024 to December 31, 2025.
- Trial name
- NCT06301906
- Testing
- LipoCol Forte Capsule 600mg twice a day
- Where
- Taiwan
- Volunteers
- 41 people
- Sponsor
- Chang Gung Memorial Hospital
Hypercholesterolemia
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R in Patients with Primary Hypercholesterolemia
- Trial name
- NCT06717360
- Testing
- AG2304T, AG2304R
- Where
- South Korea
- Volunteers
- 158 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Primary Hyperlipidemia or Mixed Dyslipidemia
Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects
This study is a Phase 3, double blind, placebo controlled, randomized, stratified, parallel group, multi-center clinical trial designed to compare the efficacy and safety of bococizumab 150 mg SC Q2wks to placebo for LDL-C…
- Trial name
- SPIRE-ASIA (NCT02947334)
- Testing
- Bococizumab
- Where
- China
- Sponsor
- Pfizer
Myalgia, Hypercholesterolemia
Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)
The purpose of this study is to assess the incidence of statin-associated myalgia (SAM) with treatment with PPD10558 versus atorvastatin in patients previously intolerant to statins.
- Conditions
- Myalgia, Hypercholesterolemia, Hyperlipidemia
- Trial name
- NCT01279590
- Testing
- PPD10558, Atorvastatin
- Where
- 67 sites in United States
- Volunteers
- 282 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Hypercholesterolemia
Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan
Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9).
- Trial name
- NCT01812707
- Testing
- Alirocumab, Atorvastatin
- Where
- 4 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Sanofi
Hypercholesterolemia
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)
This study will compare the lipid-altering efficacy and safety of switching to co-administration of ezetimibe and atorvastatin versus treatment with atorvastatin or rosuvastatin in high cardiovascular risk patients with…
- Trial name
- NCT01154036
- Testing
- ezetimibe 10 mg, atorvastatin, Comparator: rosuvastatin
- Volunteers
- 1,547 people
- Sponsor
- Organon and Co
Hypercholesterolemia
Effects of Ezetimibe on the Absorption of Oxidized Cholesterol
The purpose of this study is to test the effects of Zetia™ (ezetimibe) 10 milligrams (mg) on the absorption of oxysterol into the blood following a meal containing oxysterol.
- Trial name
- NCT00794677
- Testing
- ezetimibe
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- UCSF Benioff Children's Hospital Oakland
Hypercholesterolemia
Comparison of Ezetimibe Plus Simvastatin Versus Ezetimibe or Simvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03757)(COMPLETED)
This is a multicenter, randomized, double blind; active-controlled parallel groups study enrolling subjects with primary hypercholesterolemia.
- Trial name
- NCT00650819
- Testing
- Ezetimibe + Simvastatin, Simvastatin, Ezetimibe
- Volunteers
- 240 people
- Sponsor
- Organon and Co
Primary Hypercholesterolemia, Mixed Dyslipidemia
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)
This is a multicenter, randomized, double-blind, placebo-controlled study in participants with primary hypercholesterolemia or mixed dyslipidemia, and elevated low density lipoprotein-cholesterol (LDL-C) to assess the efficacy…
- Trial name
- NCT01274559
- Testing
- Extended-release niacin/laropiprant (ERN/LRPT)
- Volunteers
- 1,173 people
- Sponsor
- Merck Sharp & Dohme LLC
Hyperlipidemias
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Ezerosu Tab
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Ezerosu Tab
- Trial name
- NCT06225635
- Testing
- Ezerosu(monolayer tablet), Ezerosu(double layer tablet)
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Mixed Dyslipidemia, Hypercholesterolemia
Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia
The purpose of the study is to evaluate the safety and tolerability of fluvastatin 80 mg in a Chinese population. This study is not recruiting patients in the US.
- Trial name
- NCT00136799
- Testing
- Fluvastatin
- Where
- China
- Volunteers
- 325 people
- Sponsor
- Novartis
Dyslipidemia
Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol
The purpose of this study is to determine if patients with elevated cholesterol, but not taking any other lipid medication, could lower their cholesterol with administration of lapaquistat acetate, once daily (QD).
- Trial name
- NCT00143663
- Testing
- Lapaquistat Acetate
- Where
- 47 sites in United States
- Volunteers
- 361 people
- Sponsor
- Takeda
Primary Hyperlipidemia and Mixed Dyslipidemia
Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody
This is a randomized, double-blind, placebo-controlled trial to evaluate the effect of evolocumab, atorvastatin, and combination therapy on lipoprotein kinetics.
- Trial name
- FLOREY (NCT02189837)
- Testing
- Evolocumab, Atorvastatin
- Where
- 2 sites in Australia
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Amgen
Primary Hypercholesterolemia, Mixed Hyperlipidemia
Lipid Efficacy Study (0524B-022)(COMPLETED)
This is a 12-week clinical trial in patients with primary hypercholesterolemia or mixed hyperlipidemia, studying the effects of coadministered MK0524B on lipids. There will be 6 scheduled clinic visits, and 7 treatment arms.
- Trial name
- NCT00269217
- Testing
- niacin (+) laropiprant (+) simvastatin, Comparator: niacin (+) laropiprant, Comparator: simvastatin
- Volunteers
- 1,400 people
- Sponsor
- Merck Sharp & Dohme LLC
Primary Hypercholesterolemia or Mixed Hyperlipidemia
Study of QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated LDL Cholesterol
To evaluate the efficacy, safety, pharmacodynamics and immunogenicity of QLC7401 subcutaneous administration in patients with primary hypercholesterolemia or mixed hyperlipidemia with poorly controlled LDL-C elevated on optimized…
- Trial name
- NCT06750341
- Testing
- QLC7401
- Volunteers
- 156 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Hypercholesterolemia, Atherosclerosis
Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With Primary Hypercholesterolemia and Coronary Heart Disease (P03396)
The primary objective is to evaluate the efficacy and safety of coadministration of ezetimibe 10 mg with atorvastatin 10 mg in untreated subjects with primary hypercholesterolemia and coronary heart disease for whom diet and…
- Conditions
- Hypercholesterolemia, Atherosclerosis, Coronary Artery Disease
- Trial name
- NCT00650689
- Testing
- Ezetimibe + Atorvastatin, Atorvastatin
- Volunteers
- 122 people
- Sponsor
- Organon and Co
Hyperlipemia
The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia
JS002 is a recombinant humanized anti-PCSK9 monoclonal antibody. This is a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy, as well as immunogenicity of JS002 treated repeatedly in patients…
- Trial name
- NCT04781114
- Testing
- JS002
- Where
- 57 sites in China
- Volunteers
- 806 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Hypercholesterolaemia
Study of Asian Patients With Hypercholesterolaemia in the UK - Rosuvastatin 5mg Versus Atorvastatin 10mg
The purpose of this study is to compare the effectiveness and safety of rosuvastatin 5mg in lowering blood cholesterol, compared to one other medicine, atorvastatin 10mg in Asian patients in the UK.
- Trial name
- NCT00427960
- Testing
- Dietary advice, rosuvastatin, atorvastatin
- Where
- 9 sites in United Kingdom
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Primary Hypercholesterolaemia and Mixed Dyslipidemia
Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia
JS002 is a recombinant humanized anti-PCSK9 monoclonal antibody. This is a randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, PK/PD profile, immunogenicity as well as complete delivery of…
- Trial name
- NCT05621070
- Testing
- JS002
- Where
- China
- Volunteers
- 582 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.